* Apyx Medical Corp is expected to show a fall in quarterly revenue when it reports results on May 9 for the period ending March 31 2024
* The Clearwater Florida-based company is expected to report a 21.5% decrease in revenue to $9.526 million from $12.14 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.
* LSEG's mean analyst estimate for Apyx Medical Corp is for a loss of 21 cents per share.
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the last three months.
* Wall Street's median 12-month price target for Apyx Medical Corp is $2.25, above its last closing price of $1.40.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Dec. 31 2023 -0.20 -0.18 -0.28 Missed -57.7
Sep. 30 2023 -0.12 -0.11 -0.13 Missed -14.8
Jun. 30 2023 -0.07 -0.07 -0.11 Missed -58.5
Mar. 31 2023 -0.16 -0.13 -0.10 Beat 25.9
Dec. -0.15 -0.14 -0.17 Missed -19.3
31 2022
Sep. 30 2022 -0.15 -0.14 -0.17 Missed -17.2
Jun. 30 2022 -0.19 -0.19 -0.16 Beat 14.7
Jan. 1 0001 -0.14 -0.15 -0.17 Missed -15.9
This summary was machine generated May 7 at 14:29 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments